Tech Company Financing Transactions
CUTISS Funding Round
Private investors participated in a $70 million Series C venture round for CUTISS. The funding round was announced on 9/10/2025.
Transaction Overview
Company Name
Announced On
9/10/2025
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to progress with the Phase 3 trial of the lead product denovoSkin which started earlier this year, and to prepare for its commercialization.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Grabenstrasse 11
Schlieren, 8952
Switzerland
Schlieren, 8952
Switzerland
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
CUTISS is the only late-stage clinical TechBio company developing skin tissue therapeutics and dedicated to bioengineering. We are transforming skin surgery with denovoSkin�, our first-in-class personalized tissue therapy that enables automated, on-demand production of living skin at scale.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniela Marino
Browse more venture capital transactions:
Prev: 9/10/2025: Nitricity venture capital transaction
Next: 9/10/2025: Accordance venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. All VC database entries on this site come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs